ARAV.OQ
Latest Trade
5.95USDChange
0.15(+2.59%)Volume
20,031Today's Range
-
6.0152 Week Range
-
14.94As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 5.80 |
|---|---|
Open | 5.79 |
Volume | 20,031 |
3M AVG Volume | 3.11 |
Today's High | 6.01 |
Today's Low | 5.75 |
52 Week High | 14.94 |
52 Week Low | 3.41 |
Shares Out (MIL) | 16.09 |
Market Cap (MIL) | 93.31 |
Forward P/E | -2.61 |
Dividend (Yield %) | -- |
Aravive Inc - Received Guidance From U.S FDA On Phase 3 Trial Design For Avb-500 In Platinum Resistant Ovarian Cancer
Aravive Inc Says Entered Into Collaboration And License Agreement With 3D Medicines Inc On November 6
Aravive Reports Third Quarter 2020 Financial Results And Provides Corporate Updates
Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
Industry
Biotechnology & Drugs
Contact Info
RIVER OAKS TOWER
3730 KIRBY DRIVE, SUITE 1200
HOUSTON, TX
77098
United States
+1.936.3551910
https://aravive.com/Executive Leadership
Fredric N. Eshelman
Independent Chairman of the Board
Gail F. McIntyre
President, Chief Executive Officer, Director
Vinay Shah
Chief Financial Officer
Reshma Rangwala
Chief Medical Officer
Michael W. Rogers
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 1.89 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -54.77 |
Return on Equity (TTM) | -49.79 |
* ARAVIVE ADDED TO THE RUSSELL 2000® AND RUSSELL 3000® INDEXES Source text for Eikon: Further company coverage:
* ARAVIVE INC FILES FOR OFFER AND RESALE OF UP TO 931,098 SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: https://bit.ly/2Vqye36 Further company coverage:
* ARAVIVE INC - REKHA HEMRAJANI HAS RESIGNED AS COMPANY'S CHIEF EXECUTIVE OFFICER AND AS A DIRECTOR
* ARAVIVE ANNOUNCES AVB-500 IMPROVES ANTI-TUMOR EFFECTS WHEN COMBINED WITH ANTI-ANGIOGENIC BEVACIZUMAB OR PARP INHIBITOR OLAPARIB IN PRECLINICAL MODELS OF UTERINE CANCER Source text for Eikon: Further company coverage:
* ARAVIVE ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED PHASE 1/2 STUDY OF AVB-500 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA (COAXIN)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.